



Supple Figure 1:
Workflow of QuPath Analysis software to measure the DAB stain intensity




Open QuPath software, open image, select H-DAB and apply

Supple Fig 1




Go to tools, select rectangle icon and using the rectangle icon select the area of the image need to be analysed (borders of the selected area show yellow in color)

Supple Fig 1



Go to analyze, select cell detection and finally positive cell detection.


Supple Fig 1




H-Score obtained as marked by red arrow. In this case the H-score value is 22

Supple Fig 1

L1ORF1p




L1ORF2p




Black arrow mark denotes nuclear staining of L1ORF1p and L1ORF2p




Supple Fig 2: Distribution of L1ORF1p and L1ORF2p in the nucleus and cytoplasm in the operated oral cancer samples




Supple Fig 3A: IHC staining with anti-L1ORF1p (Non-recurrent) (n=35)




Supple Fig 3A: IHC staining with anti-L1ORF1p (Non-recurrent) (n=35)






Supple Fig 3A: IHC staining with anti-L1ORF1p (Non-recurrent) (n=35)



















Supple Fig 3B: IHC staining with anti-L1ORF1p (Recurrent) (n=35)




Supple Fig 3B: IHC staining with anti-L1ORF1p (Recurrent) (n=35)






Supple Fig 3B: IHC staining with anti-L1ORF1p (Recurrent) (n=35)




Supple Fig 3C: IHC staining with anti-L1ORF2p (Non-recurrent) (n=35)




Supple Fig 3C: IHC staining with anti-L1ORF2p (Non-recurrent) (n=35)






Supple Fig 3C: IHC staining with anti-L1ORF2p (Non-recurrent) (n=35)




Supple Fig 3D: IHC staining with anti-L1ORF2p (Non-recurrent) (n=35)




Supple Fig 3D: IHC staining with anti-L1ORF2p (Non-recurrent) (n=35)




Supple Fig 3D: IHC staining with anti-L1ORF2p (Non-recurrent) (n=35)




Supple Fig 4: L1ORF1p expression in established oral cancer cell line




Supple Fig 5A: IHC staining with anti-P53 (Non-recurrent) (n=25)




Supple Fig 5B: IHC staining with anti-P53 (Recurrent) (n=25)




Supple Fig 6A: IHC staining with anti-PCNA (Non-recurrent) (n=25)




Supple Fig 6B: IHC staining with anti-PCNA (Recurrent) (n=25)




Supple Fig 7A: IHC staining with CD105 (Non-recurrent) (n=25)




Supple Fig 7B: IHC staining with CD105 (Recurrent) (n=25)




Supple Fig 8A: IHC staining with anti-Ki67 (Non-recurrent) (n=25)




Supple Fig 8B: IHC staining with anti-Ki67 (Recurrent) (n=25)




Supple Fig 9A: IHC staining with anti-MMP9 (Non-recurrent) (n=25)




Supple Fig 9B: IHC staining with anti-MMP9 (Recurrent) (n=25)




Supple Fig 10A: IHC staining with anti-EGFR (Non-recurrent) (n=25)




Supple Fig 10B: IHC staining with anti-EGFR (Recurrent) (n=25)






Supple Fig 11B: IHC staining with anti-CD44 (Recurrent) (n= 25)



Supple Fig 12A: IHC staining with anti-PDL1 (Non-recurrent) (n=25)



Supple Fig 12B: IHC staining with anti-PDL1 (Recurrent) (n=25)